Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03190915 · OUTCOME

Trametinib Concentrations

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia · Source last updated 2026-07-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to cycle 12 (1 cycle = 28 days)

What was measured

Will be measured by mass spectrometry. Will be analyzed descriptively. Values will be summarized with means and standard deviations.

Analysis population: Pharmacokinetic samples were collected and run, and the assay results were reviewed. However, two experts who reviewed the data found it to be uninterpretable because it was generated using incorrect standard curves.

Groups in this outcome

Treatment (Trametinib)

Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Trametinib)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Will be measured by mass spectrometry. Will be analyzed descriptively. Values will be summarized with means and standard deviations.
groups
  1. description
    Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.
    id
    OG000
    title
    Treatment (Trametinib)
population Description
Pharmacokinetic samples were collected and run, and the assay results were reviewed. However, two experts who reviewed the data found it to be uninterpretable because it was generated using incorrect standard curves.
reporting Status
POSTED
time Frame
Up to cycle 12 (1 cycle = 28 days)
title
Trametinib Concentrations
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice